

Destinatarios y expectativas

1. Cross D. Patient satisfaction with time spent with their physician. *The Journal of family practice*, vol.47, nº (Aug) 1998.
2. Hernán M, Prieto MA, Gutiérrez JL, Martínez F, Pascua N. Expectativas calidad percibida y satisfacción de usuarios, sobre los Servicios Sanitarios en Andalucía. Documentos Escuela Andaluza de Salud Pública: Expectativas de Pacientes. Escuela Andaluza de Salud Pública. Granada, febrero 2001
3. Mira JJ, Aranz J. La satisfacción del paciente como una medida del resultado de la atención sanitaria. *Med. Clin (Barc)* 2000, 114 (Supl 3): 26-33.
4. Barker R. Characteristics of practices, general practitioners and patients related to levels of patients satisfactions with consultations. *British Journal of General Practice*. October 1996
5. Mira JJ et al. ¿Qué hace que los pacientes estén satisfechos?. Análisis de la opinión de pacientes y profesionales mediante la técnica Delphi. *Rev Calidad Asistencial* 1999; 14:165-177
6. Mira JJ et al. Semejanzas y diferencias entre satisfacción y calidad percibida. *Rev Calidad Asistencial* 2000 15:36-42

Dispepsia

1. Sander J, Van Zanten V, Flook N et al. An evidence-based approach to the management of uninvestigated dyspepsia in the era of helicobacter pylori. <i>CMAJ</i> 2000; 162: s3-s23	GPC
2. American Gastroenterological Association Medical Position Statement: Evaluation of dyspepsia. <i>Gastroenterology</i> 1998; 114: 579-581	GPC
3. Alberta Clinical Practice Guidelines Working Group. Guideline for Diagnosis and Treatment of Chronic Undiagnosed Dyspepsia in Adults. Alberta Medical Association. 2001 http://www.albertadoctors.org/resources/gastroenterology.html	GPC
4. Estudio y tratamiento del paciente con dispepsia. Grupo de trabajo de estómago. Sociedad Española de Patología Digestiva. 2000. http://www.saludaliamedica.com/Med/protocolos/sepd.htm#	GPC
5. Scottish Intercollegiate Guidelines Network (SIGN). Helicobacter pylori. Eradication therapy in dyspeptic disease August 1996. <i>Rev.</i> 1998. http://www.sign.ac.uk/pdf/sign7.pdf . August 1996.	GPC
6. Chiva N, Veldhuyzen van Zanten S J, Ferguson RA, Escobedo S, Grace E. Treating helicobacter pylori in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-helicobacter pylori positive (CADET-Hp) randomized trial. <i>BMJ</i> 2002; 324: 1012-1016.	ECC

7. Laheij RJ, Severens JL, Van de Lisdonk EH, Verbeek AL, Jansen JB. Randomized controlled trial of omeprazole or endoscopy in patients with persistent dyspepsia: a cost-effectiveness analysis. <i>Alimentary Pharmacology & Therapeutics</i> 1998; 12: 1249-1256.	ECC-ACE
8. Ofman JJ, Rabeneck L. The effectiveness of endoscopy in the management of dyspepsia: a qualitative systematic review. <i>American Journal of Medicine</i> 1999; 106: 335-346.	RS
9. Soo S, Moayyedi P, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia (Cochrane Review). In: <i>The Cochrane Library</i> , Issue 1, 2001. Oxford: Update Software.	RS
10. Delaney BC, Innes MA, Deeks J et al. Initial management strategies for dyspepsia (Cochrane Review). In: <i>The Cochrane Library</i> , issue 1, 2001. Oxford: Update software.	RS
11. Nyren O. Therapeutic trial in dyspepsia: its role in the primary care setting. <i>Scand J Gastroenterol</i> 1991; 26 (suppl 182): 61-69	R
12. Helgi Kolk, Heidi-Ingrid Maaros et al. Open access endoscopy in an epidemiological situation of high prevalence of <i>Helicobacter pylori</i> infection: applicability of the guidelines of the European Society for Primary Care Gastroenterology. <i>Family Practice</i> 2002; 19; 231-235	Cohortes
13. Brun J. Managing patients in general practice. <i>Scand J Gastroenterol</i> 1996; 215: 116-117	R
14. Talley NJ, Weaver AL, Tesmer DL, Zinsmeister AR. Lack of discriminant value of dyspepsia subgroups in patients referred for upper endoscopy. <i>Gastroenterology</i> 1993; 105: 1378-1386	O
15. Breslin NP, Thomson ABR, Bailey RJ et al. Gastric cancer and other endoscopic diagnoses in patients with benign dyspepsia. <i>Gut</i> 2000; 46: 93-97	O

Dispepsia funcional

1. Arnalich F, Martínez-Hernández PL, Capitán CF, Camacho J. Tratamiento de la dispepsia funcional y del intestino irritable. <i>Inf Ter Sist Nac Salud</i> 1998; 22: 1-8	GPC
2. Sander J, Van Zanten V, Flook N et al. An evidence-based approach to the management of uninvestigated dyspepsia in the era of helicobacter pylori. <i>CMAJ</i> 2000; 162: s3-s23	GPC
3. American Gastroenterological Association Medical Position Statement: Evaluation of dyspepsia. <i>Gastroenterology</i> 1998; 114: 579-581	GPC
4. Bazaldua OV, Schneider FD. Evaluation and management of dyspepsia. <i>Am Fam Physician</i> 1999; 60: 1773-1788	GPC
5. Alberta Clinical Practice Guidelines Working Group. Guideline for Diagnosis and Treatment of Chronic Undiagnosed Dyspepsia in Adults. Alberta Medical Association. 2001. http://www.albertadoctors.org/resources/gastroenterology.html	GPC
6. Estudio y tratamiento del paciente con dispepsia. Grupo de trabajo de estómago. Sociedad Española de Patología Digestiva. 2000. http://www.saludaliamedica.com/Med/protocolos/sepd.htm#	GPC
7. Scottish Intercollegiate Guidelines Network (SIGN). Helicobacter pylori. Eradication therapy in dyspeptic disease August 1996. Rev. 1998. http://www.Sign.ac.uk./pdf/sign7.pdf . August 1996	GPC
8. Gispert JP, Calvet X, Gabriel R, Pajares JM. Infección por Helicobacter pylori y dispepsia funcional. Metaanálisis de la eficacia del tratamiento erradicador. <i>Med Clin (Barc)</i> 2002; 118; (11); 405-9.	MA

9. Shiau JY, Shukla V K, Dube C. Canadian Coordinating Office for Health Technology Assessment. The efficacy of proton pump Inhibitors in adults with functional dyspepsia. January 2002	MA
10. Finney JS, Kinnersley N, Hughes M, O'Bryan-Tear CG, Lothian J. Meta-analysis of antisecretory and gastrokinetic compounds in functional dyspepsia. <i>Jour Clin Gastroenterol</i> 1998; 26: 312-320	MA
11. Moayyedi P, Soo S, Deeks J et al. Eradication of helicobacter pylori for non-ulcer dyspepsia (Cochrane Review). In: <i>The Cochrane Library</i> , Issue 1, 2001. Oxford: Update Software.	RS
12. Bytzer P, Hansen JM, Schaffalitzky de Muckadell OB. Empirical H2-blocker therapy or prompt endoscopy in management of dyspepsia. <i>Lancet</i> 1994; 343: 811-816	ECC
13. Hamilton J, Guthrie E, Creed F et al. A randomized controlled trial of psychotherapy in patients with chronic functional dyspepsia. <i>Gastroenterology</i> 2000; 119: 661-669	ECC
14. Wiklund I; Glise H; Jerndal P; Carlsson J; Talley NJ. Does endoscopy have a positive impact on quality of life in dyspepsia?. <i>Gastrointestinal Endoscopy</i> 1998; 47: 449-454	ECC
15. Haug TT, Svebak S, Wilhelmsen I, Berstad A, Ursin H. Psychotherapy in functional dyspepsia. <i>J Psychosom Res</i> 1994; 38: 281-291	ECC
16. Talley NJ, Meineche-Schmidt V, Pare P et al. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). <i>Alimentary Pharmacology & Therapeutics</i> 1998; 12: 1055-1065	ECC
17. Guthrie E, Creed F, Dawson D, Tomenson B. A controlled trial of psychological treatment for the irritable bowel syndrome. <i>Gastroenterology</i> 1991; 100: 450-457	ECC
18. Mearin F, Balboa A, Zárata N, Cucala M, Malagelada JR. Placebo in functional dyspepsia: symptomatic gastrointestinal motor and gastric sensorial response. <i>Am J Gastroenterol</i> 1999; 94: 116-125	Casos-Controles
19. Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GNJ. Functional gastroduodenal disorders. <i>Gut</i> 1999; 45 (supl II): 1137-1142.	R
20. Bixquert M. Tratamiento de la dispepsia funcional. <i>Revis Gastroenterol</i> 2000; 2: 269-281.	R
21. Mearin F. ¿Qué sabemos y qué ignoramos de la dispepsia funcional? <i>Rev Esp Enf Digest</i> 1991; 79: 1619-1671	R
22. Talley NJ. Therapeutic Options in nonulcer dyspepsia. <i>J Clin Gastroenterol</i> 2001; 32: 286-293	R
23. Rey Díaz-Rubio E, Díaz-Rubio M. Dispepsia funcional: la importancia de la relación médico / paciente. En: Mearin F. Dispepsia funcional tan desconocida como frecuente. <i>Doyma</i> 1998; 251-256	R
24. Berstad A, Olafsson S, Tefera S, Hatleback JG, Gilja OH, Hausken T. Controversies in dyspepsia. <i>Eur J Surg</i> 2001; 586: 4-11	R
25. Pantoflickova D, Blum AL. Should we eradicate helicobacter pylori in non-ulcer dyspepsia?. <i>Gut</i> 2001; 48: 758-761	R
26. Alonso J, Regidor E, Barrio G, Prieto L, Rodríguez C, De la Fuente L. Valores poblacionales de referencia de la versión española del Cuestionario de Salud SF-36. <i>Med Clin (Barc)</i> 1998; 111: 410-416	VDP
27. Ayuso-Mateos JL, Lasa L, Vázquez-Barquero JL. Validez interna y externa de la versión española del SF-36. <i>Med Clin (Barc)</i> 1999; : 37	VDP
28. Quintana JM, Cabriada J, López de Tejada I et al. Traducción y validación del Índice de Calidad de Vida Gastrointestinal (GIQLI). <i>Rev Esp Enferm Dig (Madrid)</i> 2001; 93: 693-699	VDP

29. Monés J, Adan A, López JS, Artés M. Validación de la versión española de la Glasgow Dyspepsia Severity Score. Rev Esp Enferm Dig (Madrid) 2001; 93: 164-169	VDP
30. Alonso J, Prieto L, Antó JM. La versión española del SF-36 Health Survey (Cuestionario de Salud SF-36): un instrumento para la medida de los resultados clínicos. Med Clin (Barc) 1995; 104: 771-776	VDP
31. Monés J, Guilera M, Artés M, López JS, Guerrero T, Fillat O. Criterios de los médicos de atención primaria para la indicación de tratamiento con procinéticos o antisecretores en pacientes con dispepsia funcional. Rev Esp Enferm Dig 2001; 93: 281-286	O
32. Caballero AM, Sofos S, Martín JL, Valenzuela M. Prevalencia de la dispepsia en España. Med Clin (Barc) 1994; 103: 717	O
33. Drossman DA, Thompson WG, Talley NJ, Funch-Jensen P, Janssens J, Whitehead WE. Identification of sub-groups of functional gastrointestinal disorders. Gastroenterology Intl 1990; 3: 159-172	C

Úlcera gástrica

1. Soll AH. Medical treatment of peptic ulcer disease. Practice guidelines. treatment of peptic ulcer disease. Practice guidelines. JAMA.1996; 275-622.	GPC
2. Bazzoli F, Pozzato P, Zagari M et al. Efficacy of lansoprazole in eradicating <i>Helicobacter Pylori</i> : a meta-analysis. Helicobacter 1998;3:195	MA
3. Huang J, Hunt RH. The importance of clarithromycin dose in the management of <i>Helicobacter Pylori</i> infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxicillin or metronidazole. Aliment Pharmacol Ther 1999; 13: 719.	MA
4. N, Rao BV, Rademaker JW et al. Meta-analysis of the efficacy of antibiotic therapy in eradicating <i>Helicobacter Pylori</i> . Am J Gastroenterol 1992;87:1716	MA
5. Schmid CH, Whiting, Cory D et al. Omeprazole plus antibiotics in the eradication of <i>Helicobacter Pylori</i> infection: a meta-regression analysis of eradication of <i>Helicobacter Pylori</i> infection: a meta-regression analysis of randomised, controlled trials. Am J Ther 1999; 6:25	MA
6. Graham DY, Schwartz JT, Cain D et al. Prospective evaluation of biopsy number in the diagnosis of esophageal and gastric carcinoma Gastroenterology 1982;82:228	ECC
7. Schepp W, Classen M. Omeprazole in the acute treatment of gastric ulcer. Scand J Gastroenterol 1989;166:58	ECC
8. Axon ATR, O'Morain CA, Bardhan KD, et al. Randomised double-blind controlled study of recurrence of gastric ulcer after treatment for eradication of gastric ulcer after treatment for eradication of <i>Helicobacter Pylori</i> infection. Br Med J 1997;314:565.	ECC
9. Van der Hulst RWM, Rauws EAJ, Köycü B et al. Prevention of ulcer recurrence after eradication of <i>Helicobacter Pylori</i> : a prospective long-term follow-up study. Gastroenterology 1997;113:1082	ECC
10. Labenz J, Børsh G. Highly significant change of the clinical course of relapsing and complicated peptic ulcer disease after cure of <i>Helicobacter Pylori</i> infection. Am J Gastroenterol 1994;89:1785	ECC
11. Bermejo F, Boixeda D, Gisbert JP et al. Efecto de la erradicación de <i>Helicobacter Pylori</i> sobre la recurrencia de la úlcera gástrica a lo largo de 12 meses. Med Clin (Barc) 2000;115:201	ECC

12. Malfertheiner P, Bayerdorffer E, Diете U et al. The GU-MACH study: the effect of 1-week omeprazole triple therapy on <i>Helicobacter Pylori</i> infection in patients with gastric ulcer. <i>Aliment Pharmacol Ther</i> 1999;13:703	ECC
13. Gschwantler M, Dragosics B, Schutze K et al. Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of <i>Helicobacter Pylori</i> - a randomised, controlled trial. <i>Aliment Pharmacol Ther</i> 1999;13: 1063	ECC
14. Ellenrieder V, Fensterer H, Wourick M et al. Influence of clarithromycin dosage on pantoprazole combined triple therapy for eradication of <i>Helicobacter Pylori</i> . <i>Aliment Pharmacol Ther</i> 1998;12:613.	ECC
15. Catalano F, Catazaro R, Bentinegna C et al. Ranitidine Bismuth citrate versus omeprazole triple therapy for the eradication of <i>Helicobacter Pylori</i> and healing of duodenal ulcer. <i>Aliment Pharmacol Ther</i> 1998; 12:59.	ECC
16. Jaup BH, Norrby A. Low-dose short term triple therapy for eradication of <i>Helicobacter pylori</i> . <i>Am J Gastroenterol</i> 1994;89;;1400	ECC
17. García S, Fuentes J, Ducóns JA et al. ¿Es suficiente y seguro un tratamiento de una semana para cicatrizar la úlcera péptica?. <i>Rev Esp Enferm Dig</i> 2000;92:5-8.	ECC
18. Boixeda D, Gisbert JP, de Rafael L, et al. Importancia de la obtención de biopsias del cuerpo gástrico en el seguimiento después del tratamiento erradicador de <i>Helicobacter pylori</i> . <i>Med Clin (Barc)</i> 1995;105:556	ECC
19. El-Zimaity HMT, Al-Assi MT, Genta RM, et al. Confirmation of successfully therapy of <i>Helicobacter pylori</i> infection: number and site of biopsies or a rapid urease test. <i>Am J Gastroenterol</i> 1995;90:1962	ECC
20. Laine L, Suchower L, Johnson E, et al. Accuracy of CLOtest after <i>Helicobacter pylori</i> therapy. <i>Gastrointest Endosc</i> 1998;47:250.	ECC
21. Santolaria S, Guirao R, Ducons JA, et al. Efectividad de la pauta "cuádruple" en los fracasos de erradicación: análisis detallado según las resistencias a claritromicina y metronidazol. <i>Gastroenterol y Hepatol.</i> 1998;21:519	ECC
22. Borda F, Martínez A, Echaría A. Clinical practice results of quadruple treatment in <i>Helicobacter pylori</i> eradication failure with OCA7. <i>Gut.</i> 1998; 43:81.	ECC
23. Stack WA, Stack WA, Knifton A, et al. Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of <i>Helicobacter pylori</i> in patients with chronic gastritis with or without peptic ulceration <i>Am J Gastroenterol</i> 1998; 93:1909-13	ECC
24. Lanás A, Remacha B, Esteve F, et al. Risk factors associated with refractory peptic ulcer. <i>Gastroenterology</i> 1995;109:1124-8	ECC
25. European <i>Helicobacter pylori</i> Study Group. Technical annex: Test used to assess <i>Helicobacter pylori</i> infection. <i>Gut</i> 1997;41 (Suppl):S10	RS
26. Soll AH. Peptic ulcer and its complications. En: Feldman M, Scharschmidt BF and Sleisenger MH (eds), <i>Gastrointestinal and liver disease</i> . Philadelphia: WA Saunders, 1998:620.	R
27. Del Valle J, Cohen H, Laine L et al. Acid peptic disorders. En: Yamada T, Alpers DH, Laine L, Owyang C, Powel DW (eds). <i>Textbook of Gastroenterology</i> . Philadelphia. Lippincott Williams and Wilkins 1999:1370.	R
28. Cotton PB and Sharnon PJ. Analysis of endoscopy and radiography in the diagnosis, follow-up and treatment of peptic ulcer disease. <i>Clin Gastroenterol</i> 1984;13:83	R
29. Humphries TJ, Merritt GJ. Review article: Drug interactions with agents used to treated acid-related disease. <i>Aliment Pharmacol Ther</i> 1999;13:18-26	R
30. Barhan KD. Is there any acid peptic disease that is refractory to proton pump inhibitors? <i>Aliment. Pharmacol Ther</i> 1993;7:13-29	R
31. Fraser GM, Earnshaw PM. The double-contrast barium meal: a correlation with endoscopy. <i>Clin Radiol</i> 1983;34:121	VPD

32. Current European concepts in the management of <i>Helicobacter Pylori</i> infection. The Maastricht Consensus Report. European <i>Helicobacter Pylori</i> Study Group. Gut 1997; 41(1):8	VPD
33. Sainz R, Borda F, Dominguez E, et al. Conferencia española de consenso sobre la infección por <i>Helicobacter Pylori</i> . Rev Esp Enferm Digest 1999;91:777	C

Úlcera duodenal

1. Scottish Intercollegiate Guidelines Network (SIGN). Helicobacter pylori. Eradication therapy in dyspeptic disease August 1996. Rev. 1998. http://www.Sign.ac.uk./pdf/sign7.pdf . August 1996	GPC
2. Jovel A J, Aymerich M, Garcia-Altes A, Serra-Prat M. Clinical practice guideline for the eradicating therapy of Helicobacter pylori infections associated to duodenal ulcer in primary care. Brief Reports CAHTA. BR98001. Catalan Agency for Health Technology Assessment. CAHTA brief reports. 1998. 14.	GPC
3. O'Brien B, Goeree R, Mohamed A H, Hunt R. Cost-effectiveness of Helicobacter pylori eradication for the long-term management of duodenal ulcer in Canada. Archives of Internal Medicine 1995;155(18):1958-1964.	MA
4. Laine L, Hopkins R J, Girardi L S. Has the impact of helicobacter pylori therapy on ulcer recurrence in the United States been overstated: a meta-analysis of rigorously designed trials. American Journal of gastroenterology 1998,93(9), 1409-1415.	MA
5. Buring S M, Winner L H, Hatton R C, Doering P L. Discontinuation rates of Helicobacter pylori treatment regimens: a meta-analysis. Pharmacotherapy 1999; 19(3): 324-332.	MA
6. Moore R A. Helicobacter pylori and peptic ulcer: a systematic review of effectiveness and an overview of the economic benefits of implementing what is known to be effective Oxford: Pain Relief Research Unit 1995: VII:7.	RS
7. Veldhuyzen van Zanten S J O, Sherman P M. Indications for treatment of helicobacter pylori infection: a systematic overview Canadian Medical Association Journal 1994; 150(2):189-198.	RS
8. Craig A-M, Davey P, Malek M, Murray F. Decision analysis of Helicobacter pylori eradication therapy using omeprazole with either clarithromycin or amoxicillin. Pharmacoeconomics 1996;10(1):79-92.	RS
9. Taylor J L, Zagari M, Murphy K, Freston J W. Pharmacoeconomic comparison of treatments for the eradication of helicobacter pylori. Archives of Internal Medicine 1997;157:87-97.	RS
10. Veldhuyzen van Zanten S J O, Sherman P M. Indications for treatment of helicobacter pylori infection: a systematic overview. Canadian Medical Association Journal 1994, 150(2), 189-198.	RS
11. Greenberg P D, Koch J, Cello J P. Clinical utility and cost effectiveness of helicobacter pylori testing for patients with duodenal and gastric ulcers. American Journal of Gastroenterology 1996;91(2):228-232.	ACE
12. Treiber G, Lambert J R. The impact of helicobacter pylori eradication on peptic ulcer healing. American Journal of Gastroenterology 1998, 93(7), 1080-1084.	ACE
13. Guidelines for clinical trials in Helicobacter pylori infection. Working Party of the European Helicobacter Study Group. Gut. Sept. 1997.	C
14. Sainz R, Borda F, Dominguez E, et al. Conferencia española de consenso sobre la infección por <i>Helicobacter Pylori</i> . Rev Esp Enferm Digest 1999;91:777	C

Enfermedad por reflujo gastroesofágico

1. Kenneth R, DeVault, Donald O.Cadstell, and The Practice Parameters Committee of the American College of Gastroenterology Updated Guidelines for the Diagnosis and Treatment of Gastroesophageal Reflux Disease.The American Journal of Gastroenterology. June 1999. Volume 94, Number 6. Pages 1434-1442.	GPC
2. Grupo de trabajo de la guía de práctica clínica sobre ERGE. Manejo del paciente con enfermedad por reflujo gastroesofágico (ERGE). Guía de práctica clínica. Barcelona: Asociación Española de Gastroenterología, Sociedad Española de Medicina Familiar y Comunitaria y Centro Cochrane Iberoamericano; 2001. Programa de Elaboración de Guías de Práctica Clínica en Enfermedades Digestivas, desde la Atención Primaria a la especializada:1	GPC
3. American Society For Gastrointestinal Endoscopy. The role of endoscopy in the management of GERD: guidelines for clinical application. From the ASGE. American Society for Gastrointestinal Endoscopy. Gastrointest. Endosc. 1999; 49(6): 834-883. Medline.	GPC
4. Dent J, Brun J, Fendrick A M, Fennery MB, Janssens J, Kahrilas Pletal. An evidence-based appraisal of reflux disease management-the General Workshop Report. Gut 1999; 44 (supl.2):S1-S16.	GPC
5. Bardhan KD, Muller-Lissner S, Bigard MA, Porro GB, Ponce J, Hosie el al. Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with Omeprazol or ranitidine. BMJ 1999; 318 (7.182):502-507.	ECC
6. Ours TM, Kavurn MS, Schilz RJ, Rithter JE. A Prospective evaluation of esophageal testing and a double-bind, randomized study of omeprazole in diagnostic and therapeutic adgorithm for chronic cough. Am J Gastroenterol 1999; 94 (11) 3131-3138.	ECC
7. El-Serag HB, Lee P, Buchner A, Inadomi JM, Gavin M, Mclarthy y Dm. Lansoprazole treatment of patients with chronic idiopathic lanjugitis: a placebo-controlled trial. Am J Gastroenterol 2001;96 (4): 979-983. Medline.	ECC
8. Gesan LB, Robbins AS, Garber A, Hornbeuger J, Triadarfilopoulos G.A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Am J Gastroenterol 2000; 95 (2): 395-407. Medline.	ACE
9. Younes Z. Johnson DA. Diagnostic evaluation in gastroesophageal reflux disease. Gastroenterol Clin North. Am 1999; 28 (4): 809-830 Medline.	R
10. Klauser AG, Schindlbeck NE, Muller-Lissner SA. Symtoms in gastro- Oesophageal reflux disease. Lancet 1990; 335:205-208 Medline	R
11. Savary M, Miller G. The esophagus. Handbook and atlas of endoscopy. Suiza: Verlag Gassman, 1978; 135-142.	R
12. Lundell L R, Dent J. Bennett J, Blum A L, Armstrong D, Galmiche JP et al. Endoscopies assessment of esophagitis. Clínica and functional correlates and further validation of the Angeles classification. Gut 1999; 45 (2): 172-180. Medline.	VPD
13. Van Herwaarden M A, Smout A J. Diagnosis of reflux disease. Baillieres Best Pract Res Clin Gastroenterol 2000; 14 (5) 759-774 Medline.	R
13. Anónimo. Systematic review of PPI and H2A in GORD. Bandolier, 1997. http://www.jr2.ox.ac.uk/Bandolier/bandopubs/gordf/gordf.htm	RS
14. Schindlbeck NE, Klauser AG, Voderholzer WA, Musler-Lissner SA. Empiric therapy for gastroesophageal reflux disease. Arch. Intern Med 1995; 156 (16): 1802-1812. Medline.	R
15. Meining A, Classen M. The role of diet and lifestyle measures in the pathogenesis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2000; 95(10):2692-2697. Medline.	R

Dispepsia y gastropatía por AINEs

1. Koch m, Dezi A, Ferrario F, Capurso L. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials. Arch Inter Med 1996; 156: 2321-32	MA
2. Hawkey CJ. Progress in prophylaxis against nonsteroidal anti-inflammatory drug-associated ulcers and erosions. Omeprazole NSAID Steering Committee. Am J Med 1998 Mar 30;104(3A):67S-74S; discussion 79S-80S-	MA
3. Ekstrom P, Carling L, Wetterhus S, Wingren PE, Anker-Hansen O, Lundegardh G, Thorhallsson E, Unge P. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. Scand J Gastroenterol 1996 Aug;31(8):753-8	MA
4. Antithrombotic trialist' (ATT) collaboration. Prevention of death, myocardial infarction, and stroke by antiplatelet therapy: collaborative meta-analysis of 266 trials involving 200.000 patients at risk of occlusive vascular events. BMJ (in press)	MA
5. Hawkey C, Laine L, Simon T. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen and placebo on the mucosa of patients with osteoarthritis. A randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2000;43:370-377	ECC
6. Hawkey CJ, Tulassay Z, Szczepanski L, van Rensburg CJ, Filipowicz-Sosnowska A, Lanas A et al Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSALIDs study. Lancet 1998; 352: 1016-1021	ECC
7. Silverstein FE, Graham DY, Senior JR, Davies HW, Strathers BJ, Bittman RM, Geis GS. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal antiinflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123:241-9	ECC
8. Raskin JB, White RH, Jaszewski R, Korsten MA, Schubert TT, Fort JG. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind, multicenter study. Am J Gastroenterol 1996;91:223-227.	ECC
9. Silverstein F, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 2000; 284:1247-1255	ECC
10. Cohen de Lara A, Gompel H, Valiente R. Dos estudios comparativos entre dosmalfato y misoprostol en la prevención de la úlcera gástrica por AINE en pacientes reumáticos. Drugs Today 2000; 36 (Supl 2): 75-81	ECC
11. Whelton A. Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2 specific inhibitors. Am J Med 2001;110:Suppl 1:33-42	ECC
12. Chan FK, To KF, Wu JCY et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002;359:9-13	ECC
13. Cullen D, Bardhan KD, Eisner M, Kogut DG, Peacock RA, Thomson JM, Hawkey CJ. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther 1998; Feb;12(2):135-40	ECC
14. Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, Yeomans ND. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998 Mar 12;338(11):727-34	ECC

15. Yeomans ND, Tulassay Z, Juhasz L, Racz I, Howard JM, van Rensburg CJ et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med. 1998 Mar 12; 338 (11): 719- 26	ECC
16. Chan FK, Chung SCS, Suen BY et al. Preventing recurrent upper gastrointestinal bleeding in patients with <i>Helicobacter pylori</i> infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001;344:967-73	ECC
17. Jüni P, Rutjes AWS and Dieppe PA. Are selective COX-2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?. BMJ 2002;324:1287-8	ECC
18. Chan FK, Sung JY, Suen R et al. Does eradication of H.Pylori impair healing of nonsteroidal anti-inflammatory drug associated bleeding peptic ulcers? A prospective randomized study?. Aliment Pharmacol Ther 1998;12:1201-1205	ECC
19. Mukherjee D, Nissen SE and Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-959	
20. Goldstein JL. Who needs prophylaxis of non-steroidal anti-inflammatory drug-induced ulcers and what is optimal prophylaxis? Eur J Gastroenterol Hepatol 2000 Jun;12 Suppl 1:S11-5	R
21. Vargas E, Cabrera L, Morón A, et al. Complicaciones gastrointestinales severas potencialmente relacionadas con el consumo de antiinflamatorios no esteroideos: coste del tratamiento hospitalario para el Sistema Nacional de Salud en nuestro país. An Med Interna (Madrid) 2001;18:564-568	R
22. Scheiman JM.Preventing NSAID Toxicity to the Upper Gastrointestinal Tract. Curr Treat Options Gastroenterol 1999 Jun;2(3):205-213	R
23. Hawkey CJ. Non-steroidal anti-inflammatory drug gastropathy. Gastroenterology 2000 Aug;119(2):521-35.	R
24. Arment PW, Childers RS. Prophylaxis and treatment of NSAID-induced gastropathy. Am Fam Physician 1997 Mar;55(4):1323-6, 1331-2	R
25. Lanás A. Efectos secundarios gastrointestinales por antiinflamatorios no esteroideos y costes en el Sistema Nacional de Salud. An Med Interna (Madrid) 2001;18:561-563	ACE
26. Prieto Yerro, C; Vargas Castrillón,E. Problemas de uso de los antiinflamatorios no esteroideos /AINE) en pacientes con patología crónica asociada. Información Terapéutica del Sistema Nacional de Salud. Vol. 24- N.º 4-2000. http://www.msc.es/farmacia/infmedic	R

Dispepsia en la embarazada

1. Winbery SL. et al. Dyspepsia in pregnancy. Obstet Gynecol Clin North Am, 2001, jun; 28 (2): 333-50	R
2. Adams S. et al. Understanding indigestion and GORD. Prof care mother child 1999; 9 (6): 143-146.	R
3. Uzam M. et al. Uzam S, Sureau G, Richard-Barthe. Heartburn and regurgitation in pregnancy. Efficacy and innocuousness of treatment with Gaviscon suspension. Rev Fr Gynecol Obstet 1988 Jul-sep; 83 (7-9): 569-72.	R
4. Sasaki A. et al. Use of peripheral dopamine antagonist (Motilium) in the treatment of dyspeptic complaints of different origin and nausea, vomiting. Ther Hung 1989; 37 (3): 172-5	R
5. Howden CW. et al. Treatment of common minor ailments. Br Med J (Clin Res Ed) 1986 Dec 13 ; 293 (6561): 1549-50.	R